Shunli Shen

973 total citations
32 papers, 689 citations indexed

About

Shunli Shen is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Shunli Shen has authored 32 papers receiving a total of 689 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 13 papers in Cancer Research and 11 papers in Oncology. Recurrent topics in Shunli Shen's work include Hepatocellular Carcinoma Treatment and Prognosis (11 papers), MicroRNA in disease regulation (6 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers). Shunli Shen is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (11 papers), MicroRNA in disease regulation (6 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers). Shunli Shen collaborates with scholars based in China, United States and Hong Kong. Shunli Shen's co-authors include Baogang Peng, Kamal G. Ishak, Michael A. Gerber, Swan N. Thung, F. Wayne Stromeyer, Shaoqiang Li, Yunpeng Hua, Ming Kuang, Ming Kuang and Longjuan Zhang and has published in prestigious journals such as Journal of Clinical Oncology, Hepatology and Biochemical and Biophysical Research Communications.

In The Last Decade

Shunli Shen

26 papers receiving 681 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shunli Shen China 16 349 249 187 179 135 32 689
Gongbo Fu China 17 471 1.3× 297 1.2× 215 1.1× 237 1.3× 182 1.3× 32 927
Lantian Tian China 11 301 0.9× 218 0.9× 128 0.7× 125 0.7× 54 0.4× 21 549
Leping Yang China 17 398 1.1× 229 0.9× 195 1.0× 52 0.3× 117 0.9× 41 725
Baoying Yuan China 14 338 1.0× 277 1.1× 129 0.7× 95 0.5× 58 0.4× 24 604
Hisanori Hatano Japan 9 318 0.9× 206 0.8× 397 2.1× 120 0.7× 128 0.9× 30 687
Catherine E. Willoughby Spain 7 221 0.6× 165 0.7× 244 1.3× 233 1.3× 60 0.4× 8 665
G Y Chau Taiwan 8 341 1.0× 139 0.6× 111 0.6× 148 0.8× 60 0.4× 14 552
Karl Quint Germany 17 457 1.3× 159 0.6× 213 1.1× 63 0.4× 77 0.6× 35 782
Teruyuki Ueda Japan 10 350 1.0× 286 1.1× 182 1.0× 328 1.8× 86 0.6× 21 830
Julia Freimuth United States 9 305 0.9× 110 0.4× 190 1.0× 89 0.5× 62 0.5× 10 613

Countries citing papers authored by Shunli Shen

Since Specialization
Citations

This map shows the geographic impact of Shunli Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shunli Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shunli Shen more than expected).

Fields of papers citing papers by Shunli Shen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shunli Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shunli Shen. The network helps show where Shunli Shen may publish in the future.

Co-authorship network of co-authors of Shunli Shen

This figure shows the co-authorship network connecting the top 25 collaborators of Shunli Shen. A scholar is included among the top collaborators of Shunli Shen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shunli Shen. Shunli Shen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Zhu, Meiyan, Meng Jin, Xiao Zhao, et al.. (2024). Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma. BMC Medicine. 22(1). 165–165. 8 indexed citations
4.
Sun, Hui‐Chuan, Xiaodong Zhu, Kui Wang, et al.. (2024). Perioperative pembrolizumab and lenvatinib for resectable hepatocellular carcinoma: A single-arm, multi-center, phase II trial (NeoLEAP-HCC).. Journal of Clinical Oncology. 42(16_suppl). 4120–4120. 3 indexed citations
5.
Huang, Yihao, Han Xiao, Wenxuan Xie, et al.. (2024). The long-term efficacy of imatinib with hepatic resection or other local treatment for gastrointestinal stromal tumours liver metastases: a retrospective cohort study. International Journal of Surgery. 110(4). 2151–2161. 1 indexed citations
6.
Peng, Xiaozhong, Huilong Li, Yunpeng Hua, et al.. (2023). A novel nomogram based on preoperative parameters to predict posthepatectomy liver failure in patients with hepatocellular carcinoma. Surgery. 174(4). 865–873. 4 indexed citations
7.
Lan, Tian, et al.. (2022). Risk predictive model based on three immune-related gene pairs to assess prognosis and therapeutic sensitivity for hepatocellular carcinoma. World Journal of Surgical Oncology. 20(1). 252–252. 2 indexed citations
8.
Jia, Yuemeng, Lin Li, Yu-Hsuan Lin, et al.. (2022). In vivo CRISPR screening identifies BAZ2 chromatin remodelers as druggable regulators of mammalian liver regeneration. Cell stem cell. 29(3). 372–385.e8. 35 indexed citations
9.
Chen, Yong, Mengchao Wei, Shunli Shen, et al.. (2022). The Combination of Radiation Therapy and Immunotherapy Is Effective and Well-Tolerated for Unresectable Biliary Tract Cancer. International Journal of Radiation Oncology*Biology*Physics. 113(4). 816–824. 4 indexed citations
10.
Shen, Rui, Lixin Ke, Qiao Li, et al.. (2022). Abnormal bile acid-microbiota crosstalk promotes the development of hepatocellular carcinoma. Hepatology International. 16(2). 396–411. 35 indexed citations
11.
Zhao, Jiawei, Yuemeng Jia, Shunli Shen, et al.. (2020). Merkel Cell Polyomavirus Small T Antigen Activates Noncanonical NF-κB Signaling to Promote Tumorigenesis. Molecular Cancer Research. 18(11). 1623–1637. 20 indexed citations
12.
Guo, Ruomi, Zhiqiang Wu, Jing Wang, et al.. (2019). Development of a Non‐Coding‐RNA‐based EMT/CSC Inhibitory Nanomedicine for In Vivo Treatment and Monitoring of HCC. Advanced Science. 6(9). 1801885–1801885. 34 indexed citations
13.
Fu, Shunjun, Shunli Shen, Shaoqiang Li, et al.. (2018). Hornerin promotes tumor progression and is associated with poor prognosis in hepatocellular carcinoma. BMC Cancer. 18(1). 815–815. 22 indexed citations
14.
Wang, Rongchang, Fan Chen, Hongxu Xu, et al.. (2018). miR-300 regulates the epithelial-mesenchymal transition and invasion of hepatocellular carcinoma by targeting the FAK/PI3K/AKT signaling pathway. Biomedicine & Pharmacotherapy. 103. 1632–1642. 42 indexed citations
15.
Wan, Daiwei, Shunli Shen, Shunjun Fu, et al.. (2016). miR-203 Suppresses the Proliferation and Metastasis of Hepatocellular Carcinoma by Targeting Oncogene ADAM9 and Oncogenic Long Non-coding RNA HULC. Anti-Cancer Agents in Medicinal Chemistry. 16(4). 414–423. 43 indexed citations
16.
Shen, Shunli, Wei Chen, Lianzhou Chen, et al.. (2015). MicroRNA-129-5p inhibits hepatocellular carcinoma cell metastasis and invasion via targeting ETS1. Biochemical and Biophysical Research Communications. 461(4). 618–623. 39 indexed citations
17.
Peng, Sui, Ye Wang, Hong Peng, et al.. (2014). Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma. Hepatology. 60(4). 1264–1277. 84 indexed citations
18.
Shen, Shunli, Shunjun Fu, Xiongqing Huang, et al.. (2014). Elevated preoperative peripheral blood monocyte count predicts poor prognosis for hepatocellular carcinoma after curative resection. BMC Cancer. 14(1). 744–744. 31 indexed citations
19.
Hu, Juan, et al.. (2012). Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts. Journal of Cancer Research and Clinical Oncology. 138(11). 1879–1890. 15 indexed citations
20.
Liang, Lijia, et al.. (2008). [Distribution of 5-FU in rat plasma and liver tissue after local 5-FU infusion].. PubMed. 28(5). 823–7. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gongbo Fu Breakdown of academic impact, for papers by Lantian Tian Breakdown of academic impact, for papers by Leping Yang Breakdown of academic impact, for papers by Baoying Yuan Breakdown of academic impact, for papers by Hisanori Hatano Breakdown of academic impact, for papers by Catherine E. Willoughby Breakdown of academic impact, for papers by G Y Chau Breakdown of academic impact, for papers by Karl Quint Breakdown of academic impact, for papers by Teruyuki Ueda Breakdown of academic impact, for papers by Julia Freimuth
Rankless by CCL
2026